The funding is anticipated to support Angel Pharma's ongoing Phase 1b/2 trial of soquelitinib for atopic dermatitis and a new Phase 2 trial of soquelitinib for asthma. Angel Pharma anticipates that it will report results from the initial cohort of the Phase 1b portion of the atopic dermatitis trial in late 2026 and will initiate the Phase 2 asthma trial in early 2027.
"We believe Angel Pharma is making strong progress with the development of soquelitinib in China," said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. "By continuing our investment in Angel Pharma, Corvus is positioned to benefit from soquelitinib clinical data generated by their trials and a significant ownership position that we believe has great potential for value creation as the opportunity for ITK inhibition in the large Chinese inflammation and immunology markets unfolds. Angel Pharma's atopic dermatitis clinical trial is enrolling patients at several major dermatology centers in China and we anticipate that the findings from this trial will extend our experience with soquelitinib in this indication."
Angel Pharma is enrolling a Phase 1b/2 clinical trial evaluating soquelitinib in patients with moderate-to-severe atopic dermatitis. This is a blinded, placebo-controlled trial that is planned to evaluate a 12-week treatment regimen in 48 patients utilizing soquelitinib doses of 100 mg twice per day, 200 mg once per day, 200 mg twice per day and 400 mg once per day. The patient eligibility and endpoints are similar to those used previously by Corvus (including that patients may have received prior systemic therapies). Depending on the results from the Phase 1b portion of the study, an additional 60-90 patients are anticipated to be enrolled in the Phase 2 portion of the study. The trial is open at several leading dermatology centers in China who have been involved in global registration trials. The study is conducted in close collaboration with Corvus.
About Corvus PharmaceuticalsCorvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company's lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is being evaluated in a registration Phase 3 clinical trial for relapsed/refractory PTCL and in a Phase 2 clinical trial for the treatment of atopic dermatitis. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the ...
